Skip to main content
Journal cover image

Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.

Publication ,  Journal Article
Lyman, GH; Barron, RL; Natoli, JL; Miller, RM
Published in: Crit Rev Oncol Hematol
March 2012

Randomized controlled trials (RCTs) have suggested a potential advantage of dose-dense chemotherapy in improving disease-free and overall survival in patients with certain malignancies. This systematic review summarizes the literature on the efficacy of dose-dense chemotherapy across various cancers (breast cancer, non-Hodgkin lymphoma [NHL], and non-small cell lung cancer) and chemotherapy regimens. Among the 17 trials identified, few reported statistically significant differences between dose-dense and standard chemotherapy, and most were small with limited statistical power. Statistically significant differences in overall survival favoring dose-dense schedules were apparent among large RCTs in potentially curative settings such as early-stage breast cancer and NHL. Clinical and treatment heterogeneity demonstrated the flexibility of the dose-dense paradigm but also precluded quantitative meta-analysis of results. Further study of dose-dense schedules based on large RCTs is needed to demonstrate the consistency and generalizability of these findings.

Duke Scholars

Published In

Crit Rev Oncol Hematol

DOI

EISSN

1879-0461

Publication Date

March 2012

Volume

81

Issue

3

Start / End Page

296 / 308

Location

Netherlands

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Oncology & Carcinogenesis
  • Male
  • Lymphoma, Non-Hodgkin
  • Lung Neoplasms
  • Humans
  • Female
  • Carcinoma, Non-Small-Cell Lung
  • Breast Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., Barron, R. L., Natoli, J. L., & Miller, R. M. (2012). Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Crit Rev Oncol Hematol, 81(3), 296–308. https://doi.org/10.1016/j.critrevonc.2011.04.010
Lyman, Gary H., Richard L. Barron, Jaime L. Natoli, and Ross M. Miller. “Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.Crit Rev Oncol Hematol 81, no. 3 (March 2012): 296–308. https://doi.org/10.1016/j.critrevonc.2011.04.010.
Lyman, Gary H., et al. “Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.Crit Rev Oncol Hematol, vol. 81, no. 3, Mar. 2012, pp. 296–308. Pubmed, doi:10.1016/j.critrevonc.2011.04.010.
Journal cover image

Published In

Crit Rev Oncol Hematol

DOI

EISSN

1879-0461

Publication Date

March 2012

Volume

81

Issue

3

Start / End Page

296 / 308

Location

Netherlands

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Oncology & Carcinogenesis
  • Male
  • Lymphoma, Non-Hodgkin
  • Lung Neoplasms
  • Humans
  • Female
  • Carcinoma, Non-Small-Cell Lung
  • Breast Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols